Prostate Cancer Diagnostics
Advertisement
Conventional imaging may understage patients with HR nmHSPC compared to PSMA-PET imaging.
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Dr. David Morris discusses the emerging role of copper-based PSMA imaging agents, specifically 64Cu-SAR-bisPSMA.
Clarity Pharmaceuticals announced that the first two participants in Co-PSMA have been dosed with its proprietary medication.
Standard risk assessment plus genomic classification for prostate cancer surveillance helps predict disease progression.
Clarity's head-to-head trial evaluates diagnostic performance of 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part one of a roundtable series on prostate cancer, focusing on defining mHSPC and mCRPC.
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
The first part of this roundtable focuses on the impact of recent research on clinical practice.
18F rhPSMA-7.3 (rhPSMA) PET/MRI imaging is a potential "one-stop shop" for detecting biochemically recurrent prostate cancer.
The panel discusses the role of PSMA imaging in prostate cancer, theranostics, and radioligand therapy.
In the first segment of this roundtable series, the panelists discuss the use of PSMA PET scans and ADT for CRPC.
The CLARIFY trial leveraged PSMA PET imaging for personalized prostate cancer treatment and detecting distant metastases.
Advanced PSMA PET imaging improved surgical outcomes for patients with high-risk prostate cancer in the CLARIFY trial.
In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients.
The COBRA study on SAR-bisPSMA for prostate cancer detection will be presented at the EANM 2024 Congress.
Dr. Pobel offers an overview of the ancillary study of the PEACE-1 trial, including how immunohistochemistry was used.
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.